Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Gilead Sciences Q2 2024 Adj. EPS $2.01 Beats $1.60 Estimate, Sales $6.954B Beat $6.719B Estimate

Author: Benzinga Newsdesk | August 08, 2024 04:03pm
Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $2.01 per share which beat the analyst consensus estimate of $1.60 by 25.62 percent. This is a 50 percent increase over earnings of $1.34 per share from the same period last year. The company reported quarterly sales of $6.954 billion which beat the analyst consensus estimate of $6.719 billion by 3.50 percent. This is a 5.38 percent increase over sales of $6.599 billion the same period last year.

Posted In: GILD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist